{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:36:26Z","timestamp":1784079386351,"version":"3.55.0"},"reference-count":43,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of General Medical Sciences (NIGMS)","award":["P20GM104932"],"award-info":[{"award-number":["P20GM104932"]}]},{"name":"National Institute of General Medical Sciences (NIGMS)","award":["Project-1"],"award-info":[{"award-number":["Project-1"]}]},{"name":"National Institute of General Medical Sciences (NIGMS)","award":["# 58-6060-6-015"],"award-info":[{"award-number":["# 58-6060-6-015"]}]},{"name":"National Institute of General Medical Sciences (NIGMS)","award":["# 70NANB19H104"],"award-info":[{"award-number":["# 70NANB19H104"]}]},{"name":"NIH","award":["P20GM104932"],"award-info":[{"award-number":["P20GM104932"]}]},{"name":"NIH","award":["Project-1"],"award-info":[{"award-number":["Project-1"]}]},{"name":"NIH","award":["# 58-6060-6-015"],"award-info":[{"award-number":["# 58-6060-6-015"]}]},{"name":"NIH","award":["# 70NANB19H104"],"award-info":[{"award-number":["# 70NANB19H104"]}]},{"name":"COBRE","award":["P20GM104932"],"award-info":[{"award-number":["P20GM104932"]}]},{"name":"COBRE","award":["Project-1"],"award-info":[{"award-number":["Project-1"]}]},{"name":"COBRE","award":["# 58-6060-6-015"],"award-info":[{"award-number":["# 58-6060-6-015"]}]},{"name":"COBRE","award":["# 70NANB19H104"],"award-info":[{"award-number":["# 70NANB19H104"]}]},{"name":"CORE-NPN","award":["P20GM104932"],"award-info":[{"award-number":["P20GM104932"]}]},{"name":"CORE-NPN","award":["Project-1"],"award-info":[{"award-number":["Project-1"]}]},{"name":"CORE-NPN","award":["# 58-6060-6-015"],"award-info":[{"award-number":["# 58-6060-6-015"]}]},{"name":"CORE-NPN","award":["# 70NANB19H104"],"award-info":[{"award-number":["# 70NANB19H104"]}]},{"name":"Research Core A, C","award":["P20GM104932"],"award-info":[{"award-number":["P20GM104932"]}]},{"name":"Research Core A, C","award":["Project-1"],"award-info":[{"award-number":["Project-1"]}]},{"name":"Research Core A, C","award":["# 58-6060-6-015"],"award-info":[{"award-number":["# 58-6060-6-015"]}]},{"name":"Research Core A, C","award":["# 70NANB19H104"],"award-info":[{"award-number":["# 70NANB19H104"]}]},{"name":"USDA ARS co-operative","award":["P20GM104932"],"award-info":[{"award-number":["P20GM104932"]}]},{"name":"USDA ARS co-operative","award":["Project-1"],"award-info":[{"award-number":["Project-1"]}]},{"name":"USDA ARS co-operative","award":["# 58-6060-6-015"],"award-info":[{"award-number":["# 58-6060-6-015"]}]},{"name":"USDA ARS co-operative","award":["# 70NANB19H104"],"award-info":[{"award-number":["# 70NANB19H104"]}]},{"name":"NIST","award":["P20GM104932"],"award-info":[{"award-number":["P20GM104932"]}]},{"name":"NIST","award":["Project-1"],"award-info":[{"award-number":["Project-1"]}]},{"name":"NIST","award":["# 58-6060-6-015"],"award-info":[{"award-number":["# 58-6060-6-015"]}]},{"name":"NIST","award":["# 70NANB19H104"],"award-info":[{"award-number":["# 70NANB19H104"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Magnolia grandiflora L. (Magnoliaceae) is a plant of considerable medicinal significance; its flowers and seeds have been used in various traditional remedies. Radioligand binding assays of n-hexane seeds extract showed displacement of radioligand for cannabinoid (CB1 and CB2) and opioid \u03b4 (delta), \u03ba (kappa), and \u00b5 (mu) receptors. Bioactivity-guided fractionation afforded 4-O-methylhonokiol (1), magnolol (2), and honokiol (3), which showed higher binding to cannabinoid rather than opioid receptors in radioligand binding assays. Compounds 1\u20133, together with the dihydro analog of 2 (4), displayed selective affinity towards CB2R (Ki values of 0.29, 1.4, 1.94, and 0.99 \u03bcM, respectively), compared to CB1R (Ki 3.85, 17.82, 14.55, and 19.08 \u03bcM, respectively). An equal mixture of 2 and 3 (1:1 ratio) showed additive displacement activity towards the tested receptors compared to either 2 or 3 alone, which in turn provides an explanation for the strong displacement activity of the n-hexane extract. Due to the unavailability of an NMR or X-ray crystal structure of bound neolignans with the CB1 and CB2 receptors, a docking study was performed to predict ligand\u2013protein interactions at a molecular level and to delineate structure-activity relationships (SAR) of the neolignan analogs with the CB1 and CB2 receptors. The putative binding modes of neolignans 1\u20133 and previously reported related analogs (4, 4a, 5, 5a, 6, 6a, and 6b) into the active site of the CB1 and CB2 receptors were assessed for the first time via molecular docking and binding free-energy (\u2206G) calculations. The docking and \u2206G results revealed the importance of a hydroxyl moiety in the molecules that forms strong H-bonding with Ser383 and Ser285 within CB1R and CB2R, respectively. The impact of a shift from a hydroxyl to the methoxy group on experimental binding affinity to CB1R versus CB2R was explained through \u2206G data and the orientation of the alkyl chain within the CB1R. This comprehensive SAR, influenced by the computational study and the observed in vitro displacement binding affinities, has indicated the potential of magnolia neolignans for developing new CB agonists for potential use as analgesics, anti-inflammatory agents, or anxiolytics.<\/jats:p>","DOI":"10.3390\/molecules28031253","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T02:01:18Z","timestamp":1675044078000},"page":"1253","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["In Vitro and In Silico Studies of Neolignans from Magnolia grandiflora L. Seeds against Human Cannabinoids and Opioid Receptors"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-8254","authenticated-orcid":false,"given":"Pankaj","family":"Pandey","sequence":"first","affiliation":[{"name":"National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Kumarihamy","sequence":"additional","affiliation":[{"name":"National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-5336","authenticated-orcid":false,"given":"Krishna","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, The University of Mississippi, University, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0257-860X","authenticated-orcid":false,"given":"Mohamed A. M.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet A.","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of BioMolecular Sciences, Division of Medicinal Chemistry and Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murrell","family":"Godfrey","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, The University of Mississippi, University, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-1842","authenticated-orcid":false,"given":"Robert J.","family":"Doerksen","sequence":"additional","affiliation":[{"name":"Department of BioMolecular Sciences, Division of Medicinal Chemistry and Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Muhammad","sequence":"additional","affiliation":[{"name":"National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: New agents, targets and indications","volume":"16","author":"Hauser","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/s41366-020-0577-8","article-title":"Anti-obesity therapy with peripheral CB1 blockers: From promise to safe(?) practice","volume":"44","author":"Quarta","year":"2020","journal-title":"Int. J. Obes."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1476-5381.2011.01352.x","article-title":"The case for peripheral CB(1) receptor blockade in the treatment of visceral obesity and its cardiometabolic complications","volume":"163","author":"Kunos","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Soler-Cedeno, O., and Xi, Z.-X. (2022). Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge. Cells, 11.","DOI":"10.3390\/cells11203262"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Pandey, P., Roy, K.K., Liu, H., Ma, G., Pettaway, S., Alsharif, W.F., Gadepalli, R.S., Rimoldi, J.M., McCurdy, C.R., and Cutler, S.J. (2018). Structure-based identification of potent natural product chemotypes as cannabinoid receptor 1 inverse agonists. Molecules, 23.","DOI":"10.3390\/molecules23102630"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations","volume":"232","author":"GGaliegue","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/157015907780866884","article-title":"The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration","volume":"5","author":"Ashton","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1096\/fj.09-129478","article-title":"The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia\/reperfusion-induced cardiomyopathy","volume":"23","author":"Defer","year":"2009","journal-title":"FASEB J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.1021\/jm4005626","article-title":"Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists","volume":"56","author":"Han","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.117.245522","article-title":"Selective cannabinoid 2 receptor stimulation reduces tubular epithelial cell damage after renal ischemia-reperfusion Injury","volume":"364","author":"Pressly","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13879","DOI":"10.1523\/JNEUROSCI.2711-15.2015","article-title":"Pain and poppies: The good, the bad, and the ugly of opioid analgesics","volume":"35","author":"Trang","year":"2015","journal-title":"J. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/clpt.2011.188","article-title":"Cannabinoid-opioid interaction in chronic pain","volume":"90","author":"Abrams","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104795","DOI":"10.1016\/j.neubiorev.2022.104795","article-title":"Role of Shankhpushpi (Convolvulus pluricaulis) in neurological disorders: An umbrella review covering evidence from ethnopharmacology to clinical studies","volume":"140","author":"Sharma","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_14","first-page":"1082","article-title":"Magnolia grandiflora L","volume":"10","year":"1759","journal-title":"Syst. Nat. Ed."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10787-009-7013-y","article-title":"Neolignans from North American Magnolia species with cyclooxygenase 2 inhibitory activity","volume":"17","author":"Khan","year":"2009","journal-title":"Inflammopharmacology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pharmthera.2011.01.010","article-title":"Therapeutic applications of compounds in the Magnolia family","volume":"130","author":"Lee","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/hup.2595","article-title":"Is there a potential of misuse for Magnolia officinalis compounds\/metabolites?","volume":"32","author":"Schifano","year":"2017","journal-title":"Hum. Psychopharmacol."},{"key":"ref_18","first-page":"769","article-title":"Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase-2","volume":"38","author":"Singh","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1089\/jmf.2010.1111","article-title":"Anxiolytic-like effects of 4-O-methylhonokiol isolated from Magnolia officinalis through enhancement of GABAergic transmission and chloride influx","volume":"14","author":"Han","year":"2011","journal-title":"J. Med. Food."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zhang, B., Wang, P.P., Hu, K.L., Li, L.N., Yu, X., Lu, Y., and Chang, H.S. (2019). Antidepressant-Like effect and mechanism of action of honokiol on the mouse lipopolysaccharide (LPS) depression model. Molecules, 24.","DOI":"10.3390\/molecules24112035"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Singha, S.K., Muhammad, I., Ibrahim, M.A., Wang, M., Ashpole, N.M., and Shariat-Madar, Z. (2019). 4-O-Methylhonokiol influences normal cardiovascular development in medaka embryo. Molecules, 24.","DOI":"10.3390\/molecules24030475"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.phytochem.2012.08.014","article-title":"Biphenyl-type neolignans from Magnolia officinalis and their anti-inflammatory activities","volume":"85","author":"Kuo","year":"2013","journal-title":"Phytochemistry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fphar.2018.00140","article-title":"Antihyperalgesic properties of honokiol in inflammatory pain models by targeting of NF-\u03baB and Nrf2 signaling","volume":"9","author":"Khalid","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1016\/j.bmc.2014.10.027","article-title":"Structural analogues of the natural products magnolol and honokiol as potent allosteric potentiators of GABA(A) receptors","volume":"22","author":"Fuchs","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Stout, K., Bernaskova, M., Miller, G.W., Hufner, A., and Schuehly, W. (2018). Bioinspired honokiol analogs and their evaluation for activity on the norepinephrine transporter. Molecules, 23.","DOI":"10.3390\/molecules23102536"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jep.2004.01.013","article-title":"Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones","volume":"91","author":"Kong","year":"2004","journal-title":"J. Ethnopharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/ml300235q","article-title":"Magnolia extract, magnolol, and metabolites: Activation of cannabinoid CB2 receptors and blockade of the related GPR55","volume":"4","author":"Rempel","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_28","unstructured":"Anavi-Goffer, S., and Gertsch, J. (2016). CB2 Receptor Ligands for the Treatment of Psychiatric Disorders. (1498379858369718886-09486419), Google Patents, Available online: storage.googleapis.com."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Fuchs, A., Rempel, V., and M\u00fcller, C.E. (2013). The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077739"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.chembiol.2011.05.012","article-title":"Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists","volume":"18","author":"Schuehly","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1055\/a-0642-1966","article-title":"Safety and toxicology of magnolol and honokiol","volume":"84","author":"Sarrica","year":"2018","journal-title":"Planta Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cell.2018.12.011","article-title":"Crystal structure of the human cannabinoid receptor CB2","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nature23272","article-title":"Crystal structures of agonist-bound human cannabinoid receptor CB1","volume":"547","author":"Hua","year":"2017","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/10826070903574063","article-title":"Isolation and purification of phenolic compounds from magnoliae officinalis by preparative high-performance liquid chromatography","volume":"33","author":"Liu","year":"2010","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Chen, Y.H., Lu, M.H., Guo, D.S., Zhai, Y.Y., Miao, D., Yue, J.Y., Yuan, C.H., Zhao, M.M., and An, D.R. (2019). An antifungal effect of magnolol and honokiol from Magnolia officinalis on Alternaria alternata causing Tobacco Brown Spot. Molecules, 24.","DOI":"10.3390\/molecules24112140"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1007\/s00044-014-0972-6","article-title":"Evaluation of phytocannabinoids from high potency Cannabis sativa using in vitro bioassays to determine structure-activity relationships for cannabinoid receptor 1 and cannabinoid receptor 2","volume":"23","author":"Husni","year":"2014","journal-title":"Med. Chem. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"103545","DOI":"10.1016\/j.arabjc.2021.103545","article-title":"1, 2, 3-Triazole derivatives as highly selective cannabinoid receptor type 2 (CB2) agonists","volume":"15","author":"Tarawneh","year":"2022","journal-title":"Arab J. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1021\/jo3026753","article-title":"Heteroatom analogues of hydrocodone: Synthesis and biological activity","volume":"78","author":"Giacometti","year":"2013","journal-title":"J. Org. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J. Comput. Aid. Mol. Des."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: A Force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-2836(02)00470-9","article-title":"On the role of the crystal environment in determining protein side-chain conformations","volume":"320","author":"Jacobson","year":"2002","journal-title":"J. Mol. Biol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/3\/1253\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:17:15Z","timestamp":1760120235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/3\/1253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["molecules28031253"],"URL":"https:\/\/doi.org\/10.3390\/molecules28031253","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}